James Court began his research career at the Liverpool Insect Testing Establishment at Liverpool School of Tropical Medicine (LSTM) where he was responsible for rearing insecticide-resistant and susceptible mosquito colonies, conducting bioassays to evaluate resistance to new and repurposed insecticides, and maintaining resistance profiles for various mosquito strains.

He transitioned into clinical research and now works as a Senior Research Technician and Laboratory Study Coordinator at the Liverpool Vaccine Group, specialising in controlled human infection model studies and clinical trials, with a primary focus on pneumococcal research. His work explores host-pathogen interactions, immune responses, and microbial mechanisms of infection, contributing to the development of vaccines and therapeutics.

James plays a key role in preparing pneumococcal challenge agents for clinical exposure and determining pneumococcal carriage status in experimental human pneumococcal challenge trials, as well as overseeing laboratory operations for early-phase vaccine and infection studies. With expertise in good clinical laboratory practice, he ensures the integrity of sample processing, data management, and regulatory compliance in high-containment laboratory environments.

He has worked on early-phase vaccine trials and experimental human pneumococcal challenge studies, including the COVID-19 ChAdOx vaccine trial, Middle East respiratory syndrome vaccine trial, SARS-CoV-2 research for rapid diagnostic tests, and salmonella paratyphi A vaccine trials.

As a research integrity champion at LSTM, James supports ethical research conduct and promote a culture of transparency and excellence.

With a commitment to scientific discovery and innovation, he strives to advance pneumococcal and infectious disease research that inform global public health strategies.